This analysis examines the historical and forecast performance for Gilead in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Scope

Highlights

Reasons to Purchase

Benchmark Gilead's performance against key rivals in the ethical pharmaceutical sector See how the strong sales growth of Atripla will be tempered by the cannibalization of Truvada's revenues Learn how the acquisition of Myogen has provided Gilead with a major growth driver and a pathway to therapeutic diversification.